Alkermes plc. (ALKS) stock

ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value

$47.89+1.42 (+3.06%)

Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –

Alkermes EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Alkermes's EV/EBITDA was 49.6× on Nov 11, 2026, against 9.7× a year earlier. Over the last 5 years it ranged from 6.2× to 249.9×, with a median of 15.6×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	49.6×	+40.6
2025	Dec 31, 2025	9.0×	−2.4
2024	Dec 31, 2024	11.4×	+4.1
2023	Dec 29, 2023	7.3×	−38.7
2022	Dec 30, 2022	46.0×	−180.5
2021	Dec 31, 2021	226.5×	−758.2
2019	Apr 30, 2019	984.7×	+529.6
2018	Dec 31, 2018	455.1×	+426.9
2016	Jan 29, 2016	28.1×	−45.6
2015	Dec 31, 2015	73.8×	+22.5
2014	Dec 31, 2014	51.3×	+15.4
2013	Dec 31, 2013	35.9×	−13.0
2012	Dec 31, 2012	49.0×	–